Rep. Mike Kelly Sells Abbott Laboratories (NYSE:ABT) Shares

Representative Mike Kelly (Republican-Pennsylvania) recently sold shares of Abbott Laboratories (NYSE:ABT). In a filing disclosed on August 12th, the Representative disclosed that they had sold between $1,001 and $15,000 in Abbott Laboratories stock on July 17th. The trade occurred in the Representative’s “VICTORIA KELLY TRUST ICA” account.

Representative Mike Kelly also recently made the following trade(s):

• Sold $15,001 – $50,000 in shares of PepsiCo (NASDAQ:PEP) on 7/17/2026.
• Sold $1,001 – $15,000 in shares of Walt Disney (NYSE:DIS) on 7/17/2026.

Abbott Laboratories Stock Performance

NYSE ABT opened at $111.27 on Friday. The firm’s 50 day simple moving average is $97.67 and its 200 day simple moving average is $99.83. The company has a current ratio of 1.38, a quick ratio of 0.97 and a debt-to-equity ratio of 0.57. Abbott Laboratories has a 1 year low of $81.97 and a 1 year high of $137.49. The firm has a market capitalization of $192.53 billion, a price-to-earnings ratio of 36.01, a P/E/G ratio of 2.15 and a beta of 0.59.

Abbott Laboratories (NYSE:ABT) last released its earnings results on Thursday, July 16th. The healthcare product maker reported $1.31 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.28 by $0.03. The firm had revenue of $12.59 billion for the quarter, compared to analysts’ expectations of $12.52 billion. Abbott Laboratories had a return on equity of 17.69% and a net margin of 11.65%.The business’s revenue for the quarter was up 13.0% on a year-over-year basis. During the same quarter in the previous year, the business posted $1.26 earnings per share. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. As a group, research analysts expect that Abbott Laboratories will post 5.52 earnings per share for the current fiscal year.

Abbott Laboratories Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Monday, August 17th. Stockholders of record on Wednesday, July 15th will be given a $0.63 dividend. The ex-dividend date is Wednesday, July 15th. This represents a $2.52 annualized dividend and a dividend yield of 2.3%. Abbott Laboratories’s payout ratio is presently 81.55%.

Abbott Laboratories News Roundup

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Alphabet AI partnership expands Abbott’s growth opportunity: Abbott and Alphabet announced a multiyear collaboration integrating data from Abbott’s over-the-counter Lingo continuous glucose monitor into the Google Health app. Google’s AI Health Coach is expected to use the data to provide personalized recommendations, potentially increasing Lingo adoption and strengthening Abbott’s position in consumer digital health. Can Abbott Laboratories’ Lingo Partnership With Alphabet Unlock a New Era of AI-Powered Health?
• Positive Sentiment: Wolfe Research upgraded ABT to Outperform: The firm raised its rating from “Peer Perform” and set a $130 price target, implying substantial upside from recent trading levels. The upgrade indicates improving analyst confidence in Abbott’s earnings durability and growth prospects.
• Positive Sentiment: Established Pharmaceuticals remains a growth driver: Abbott’s Established Pharmaceutical Products division is benefiting from emerging-market demand, a broad branded-generics portfolio and biosimilar opportunities. This provides diversification beyond the company’s medical-device businesses. What’s Backing Abbott’s Established Pharmaceuticals Division Growth
• Neutral Sentiment: Recent trading strength reflects broad investor support: Abbott outperformed some medical-product peers during a recent strong market session, while bullish commentary has highlighted the company’s diversified portfolio and long-term growth potential. Abbott Laboratories Stock Outperforms Competitors on Strong Trading Day
• Negative Sentiment: Valuation remains a potential constraint: With a forward-looking earnings multiple above 36 and the stock already well above its recent moving averages, further gains may require continued earnings execution and evidence that newer initiatives such as Lingo can materially contribute to revenue.

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on ABT shares. Daiwa Securities Group downgraded Abbott Laboratories from an “outperform” rating to a “neutral” rating and set a $92.00 price objective for the company. in a report on Wednesday, April 22nd. Royal Bank Of Canada reaffirmed an “outperform” rating and set a $130.00 price objective on shares of Abbott Laboratories in a research report on Friday, July 17th. Bank of America dropped their price target on Abbott Laboratories from $120.00 to $102.00 in a research note on Friday, June 12th. Robert W. Baird began coverage on shares of Abbott Laboratories in a report on Wednesday, July 1st. They issued an “outperform” rating and a $121.00 target price on the stock. Finally, TD Cowen reiterated a “buy” rating and issued a $115.00 target price on shares of Abbott Laboratories in a report on Friday, July 17th. Three research analysts have rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and four have given a Hold rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $118.67.

Institutional Trading of Abbott Laboratories

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Port Capital LLC purchased a new stake in shares of Abbott Laboratories in the second quarter worth $562,000. Windsor Advisory Group LLC bought a new position in Abbott Laboratories in the 2nd quarter worth about $243,000. Freestone Grove Partners LP purchased a new stake in shares of Abbott Laboratories in the 2nd quarter valued at about $124,572,000. Caisse de depot et placement du Quebec bought a new position in shares of Abbott Laboratories in the second quarter worth approximately $70,978,000. Finally, Gallagher Fiduciary Advisors LLC purchased a new stake in Abbott Laboratories in the second quarter valued at approximately $411,000. Institutional investors own 75.18% of the company’s stock.

About Representative Kelly

Mike Kelly (Republican Party) is a member of the U.S. House, representing Pennsylvania’s 16th Congressional District. He assumed office on January 3, 2019. His current term ends on January 3, 2027.

Kelly (Republican Party) is running for re-election to the U.S. House to represent Pennsylvania’s 16th Congressional District. He declared candidacy for the 2026 election.

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.